Chronic Graft Versus Host Disease
Specialty Channel

Featured Article
True or False: Vedolizumab could help prevent aGVHD by inhibiting the migration of both naive and activated lymphocytes into gut-associated lymphoid tissues and the lamina propria.
Study findings showed that vedolizumab 300 mg was tolerable and led to low incidence of overall and lower-intestinal aGVHD in patients who undergo allo-HSCT.
True or false: The efficacy of allo-HCT depends on the ability of donor T-cells to mediate a potent anti-tumor response in transplant recipients, known as the graft-versus-tumor effect.
True or False: This year, Ruxolitinib, a selective Janus kinase inhibitor, showed potential efficacy for glucocorticoid-refractory acute GVHD in a phase 2 trial.
True or False: Itpkb signaling is essential to drive acute GVHD pathogenesis and sustain active chronic GVHD.
In a phase 2 clinical trial, which prophylaxis regimens yielded the best GVHD-free relapse-free survival in adults who underwent reduced-intensity conditioning allogeneic hematopoietic cell…
True or False: Intact inositol-trisphosphate 3-kinase B signaling is essential to drive acute graft versus host disease pathogenesis and sustain active chronic GVHD.
True or False: Although DKK3 is a novel biomarker for chronic graft-versus-host disease, further studies are needed to determine the biological functions of DKK3 in the pathogenesis of cGVHD.
True or False: Study findings suggest that an association exists between plasma DKK3 concentrations and nonrelapse mortality in patients with chronic graft-versus-host disease.

News

Study findings showed that vedolizumab 300 mg was tolerable and led to low incidence of overall and lower-intestinal aGVHD in patients who undergo allo-HSCT.
Study findings suggest that an association exists between plasma DKK3 concentrations and nonrelapse mortality in patients with cGVHD.
In a phase 2 clinical trial, ruxolitinib was well-tolerated and led to responses in >50% of patients with steroid-refractory acute GVHD.
Ruxolitinib significantly improved efficacy outcomes over common therapy options for patients with glucocorticoid-refractory acute GVHD after allogeneic stem cell transplantation.

Interactive Features

True or False: Vedolizumab could help prevent aGVHD by inhibiting the migration of both naive and activated lymphocytes into gut-associated lymphoid tissues and the lamina propria.
True or false: The efficacy of allo-HCT depends on the ability of donor T-cells to mediate a potent anti-tumor response in transplant recipients, known as the graft-versus-tumor effect.
True or False: This year, Ruxolitinib, a selective Janus kinase inhibitor, showed potential efficacy for glucocorticoid-refractory acute GVHD in a phase 2 trial.
True or False: Itpkb signaling is essential to drive acute GVHD pathogenesis and sustain active chronic GVHD.
Stay in the know.
OncNet Newsletter